ARK Invest Doubles Down: Bullish Bets on BitMine Signal Crypto Confidence Surge
Cathie Wood's ARK Invest just turbocharged its crypto portfolio—BitMine and Bullish are the new darlings. Here's why Wall Street's watching.
### The Big Bet: ARK's Crypto Playbook
No half-measures here. ARK's latest filings reveal aggressive accumulation of BitMine shares and Bullish derivatives—classic Wood moves. 'Disruptive innovation' isn't just a buzzword in their prospectus anymore.
### Why These Picks? (Besides FOMO)
BitMine's infrastructure dominance pairs with Bullish's institutional liquidity like whiskey and risk appetite. Meanwhile, traditional finance still thinks 'blockchain' is a spreadsheet upgrade.
### The Punchline
While Jamie Dimon reheats his 'crypto is pet rock' speech, ARK's buying the dip—and the rally. Maybe hedge funds should try reading whitepapers instead of Bloomberg terminals.
ARK’s broader crypto push
These moves are part of a larger trend at ARK Invest, which has been on a crypto-buying spree in recent weeks. Last week alone, the firm added 542,269 shares of Circle (CRCL), spending about $46 million over two days as the stock’s price continued to slide.
ARK’s latest purchases also follow earlier additions to BitMine. On Thursday, the firm acquired 242,347 shares for roughly $8.9 million as BitMine’s stock dipped below $37. This comes after ARK unloaded $109.6 million worth of shares across ARKK, ARKW, and ARKF on June 23.
Recently, the firm also invested $10 million in Securitize, a tokenization company backed by BlackRock, making it the eighth-largest holding in the ARK Venture Fund and accounting for about 3.25% of the fund’s assets.
Moves across other ARK ETFs
Beyond its crypto exposure, ARK made several adjustments across its broader ETF lineup. ARKK increased its stakes in biotech names such as Twist Bioscience, Beam Therapeutics, Tempus AI and CRISPR Therapeutics, while reducing positions in Iridium Communications, Veracyte, and Pinterest.
ARKW and ARKF continued adding to BitMine and Bullish, while the biotech-focused ARKG fund expanded its holdings in Tempus AI, Beam, Twist Bioscience, CRISPR and Regeneron, and trimmed Guardant Health, Natera, and Veracyte.
Also Read: Harvard’s Latest Filing Shows Major Boost in Bitcoin ETF Holdings
